Donald Trump Announces Phased 200% Tariff on Generic Medicines: Impact on Indian Pharma Exports

US President Donald Trump has announced plans to impose steep tariffs of up to 200% on imported generic drugs in a phased manner, aiming to bring pharmaceutical manufacturing back to the United States.

Key Highlights:
- Phased Tariff Structure: Starting August 1, generic medicines will enjoy a 0% tariff for the first two years. Following this grace period, tariffs will increase to 100% for one year, and subsequently rise to 200%.
- Impact on India: India, known as the 'pharmacy of the world', exported $9.7 billion worth of generic medicines to the US in 2025 (accounting for 38% of its total global pharma exports). With every 1 in 5 generic drugs in the US originating from India, the two-year grace period offers a crucial cushion for Indian companies to strategize, expand local US manufacturing, or form partnerships.